Top

Cancer Cell International

Published in:

Open Access 01-12-2018 | Primary research

Identification of long non-coding RNA competing interactions and biological pathways associated with prognosis in pediatric and adolescent cytogenetically normal acute myeloid leukemia

Authors: Xuejiao Yin, Sui Huang, Ruiqi Zhu, Fengjuan Fan, Chunyan Sun, Yu Hu

Published in: Cancer Cell International | Issue 1/2018

Abstract

Background

LncRNAs can regulate miRNAs and mRNAs by sequestering and binding them. Indeed, many researchers have reported lncRNA mediated-competing endogenous RNAs (ceRNAs) could regulate the progression of solid tumors. However, the roles of ceRNA in acute myeloid leukemia (AML), especially in pediatric and adolescent AML, were not completely expounded.

Materials and methods

27 cytogenetically normal acute myeloid leukemia (CN-AML) patients under 18 years old with corresponding clinical data were selected from the cancer genome atlas (TCGA), which was a large sample sequencing database of RNA sequencing. We constructed a survival specific ceRNA network, and investigated its associations with patients’ clinical information by analyzing the data from TCGA.

Results

We identified survival specific lncRNAs, miRNAs and mRNAs, and constructed a survival specific ceRNA network of CN-AML patients and a weighted correlation network. Furthermore, we identified 4 biological pathways associated with OS and selected the most enriched pathway ‘Transcriptional misregulation in cancer’ to verify that it could accurately predict younger CN-AML patients’ prognosis to guide treatment.

Conclusions

We successfully constructed a survival specific ceRNA network which could provide a new approach to lncRNA research in younger CN-AML. Importantly, we constructed a weighted correlation network to overcome the difficulty in biological interpretation of individual genes.

Available only for authorised users

Kunej T, Obsteter J, Pogacar Z, Horvat S, Calin GA. The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring. Crit Rev Clin Lab Sci. 2014;51(6):344–57. https://doi.org/10.3109/10408363.2014.944299.CrossRefPubMed

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353–8. https://doi.org/10.1016/j.cell.2011.07.014.CrossRefPubMedPubMedCentral

Song X, Cao G, Jing L, et al. Analysing the relationship between lncRNA and protein-coding gene and the role of lncRNA as ceRNA in pulmonary fibrosis. J Cell Mol Med. 2014;18(6):991–1003. https://doi.org/10.1111/jcmm.12243.CrossRefPubMedPubMedCentral

Pan W, Liu L, Wei J, et al. A functional lncRNA HOTAIR genetic variant contributes to gastric cancer susceptibility. Mol Carcinog. 2016;55(1):90–6. https://doi.org/10.1002/mc.22261.CrossRefPubMed

Huang C, Cao L, Qiu L, et al. Upregulation of H19 promotes invasion and induces epithelial-to-mesenchymal transition in esophageal cancer. Oncol Lett. 2015;10(1):291–6. https://doi.org/10.3892/ol.2015.3165.CrossRefPubMedPubMedCentral

Loewen G, Jayawickramarajah J, Zhuo Y, Shan B. Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol. 2014;7:90. https://doi.org/10.1186/s13045-014-0090-4.CrossRefPubMedPubMedCentral

Junge A, Zandi R, Havgaard JH, Gorodkin J, Cowland JB. Assessing the miRNA sponge potential of RUNX1T1 in t (8, 21) acute myeloid leukemia. Gene. 2017;615:35–40. https://doi.org/10.1016/j.gene.2017.03.015.CrossRefPubMed

Ding Y, Wang ZC, Zheng Y, et al. C-Myc functions as a competing endogenous RNA in acute promyelocytic leukemia. Oncotarget. 2016;7(35):56422–30. https://doi.org/10.18632/oncotarget.10896.PubMedPubMedCentralCrossRef

Chen L, Wang W, Cao L, Li Z, Wang X. Long non-coding RNA CCAT1 acts as a competing endogenous RNA to regulate cell growth and differentiation in acute myeloid leukemia. Mol Cells. 2016;39(4):330–6. https://doi.org/10.14348/molcells.2016.2308.CrossRefPubMedPubMedCentral

10.

Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115–36. https://doi.org/10.1016/s0268-960x(03)00040-7.CrossRefPubMed

11.

Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187–205. https://doi.org/10.1182/blood-2012-03-362608.CrossRefPubMed

12.

Moreaux J, Klein B, Bataille R, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96(4):574–82. https://doi.org/10.3324/haematol.2010.033456.CrossRefPubMed

13.

Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50. https://doi.org/10.1073/pnas.0506580102.CrossRefPubMedPubMedCentral

14.

Ivliev AE, t Hoen PA, Borisevich D, Nikolsky Y, Sergeeva MG. Drug repositioning through systematic Mining of Gene Coexpression Networks in cancer. PloS ONE. 2016;11(11):e0165059. https://doi.org/10.1371/journal.pone.0165059.CrossRefPubMedPubMedCentral

15.

Jasielec J, Saloura V, Godley LA. The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia. 2014;28(9):1765–73. https://doi.org/10.1038/leu.2014.163.CrossRefPubMed

16.

Matveeva A, Kovalevska L, Kholodnyuk I, Ivanivskaya T, Kashuba E. The TGF-beta—SMAD pathway is inactivated in cronic lymphocytic leukemia cells. Exp Oncol. 2017;39(4):286–90.PubMed

17.

Peng JM, Bera R, Chiou CY, et al. Actin cytoskeleton remodeling drives epithelial-mesenchymal transition for hepatoma invasion and metastasis. Hepatology. 2017. https://doi.org/10.1002/hep.29678.CrossRefPubMed

18.

Mollinedo F, de la Iglesia-Vicente J, Gajate C, et al. In vitro and in vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res. 2010;16(7):2046–54. https://doi.org/10.1158/1078-0432.ccr-09-2456.CrossRefPubMed

19.

Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33(27):2949–62. https://doi.org/10.1200/jco.2015.62.8289.CrossRefPubMedPubMedCentral

20.

Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277–82. https://doi.org/10.1038/sj.leu.2402765.CrossRefPubMed

21.

Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–74. https://doi.org/10.1182/blood-2009-07-235358.CrossRefPubMed

22.

Khandelwal A, Bacolla A, Vasquez KM, Jain A. Long non-coding RNA: a new paradigm for lung cancer. Mol Carcinog. 2015;54(11):1235–51. https://doi.org/10.1002/mc.22362.CrossRefPubMed

23.

Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;6:37. https://doi.org/10.1186/1756-8722-6-37.CrossRefPubMedPubMedCentral

24.

Hughes JM, Legnini I, Salvatori B, et al. C/EBPalpha-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia. Oncotarget. 2015;6(21):18534–44. https://doi.org/10.18632/oncotarget.4069.CrossRefPubMedPubMedCentral

25.

Wang Y, Zhou Q, Ma JJ. High expression of lnc-CRNDE presents as a biomarker for acute myeloid leukemia and promotes the malignant progression in acute myeloid leukemia cell line U937. Eur Rev Med Pharmacol Sci. 2018;22(3):763–70. https://doi.org/10.26355/eurrev_201802_14310.PubMedCrossRef

26.

Fernando TR, Contreras JR, Zampini M, et al. The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. Mol Cancer. 2017;16(1):126. https://doi.org/10.1186/s12943-017-0692-x.CrossRefPubMedPubMedCentral

27.

Cheng H, Huang CM, Wang Y, et al. Microarray profiling and co-expression network analysis of the lncRNAs and mRNAs associated with acute leukemia in adults. Mol Biosyst. 2017;13(6):1102–8. https://doi.org/10.1039/c6mb00874g.CrossRefPubMed

28.

Johnsson P, Ackley A, Vidarsdottir L, et al. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat Struct Mol Biol. 2013;20(4):440–6. https://doi.org/10.1038/nsmb.2516.CrossRefPubMedPubMedCentral

29.

Sen R, Ghosal S, Das S, Balti S, Chakrabarti J. Competing endogenous RNA: the key to posttranscriptional regulation. Sci World J. 2014;2014:896206. https://doi.org/10.1155/2014/896206.CrossRef

30.

Yuan JH, Yang F, Wang F, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25(5):666–81. https://doi.org/10.1016/j.ccr.2014.03.010.CrossRefPubMed

31.

Jin X, Cai L, Wang C, et al. CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3. Cell Death Dis. 2018;9(3):318. https://doi.org/10.1038/s41419-018-0350-2.CrossRefPubMedPubMedCentral

32.

Sun T, Wang X, He HH, et al. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2014;33(21):2790–800. https://doi.org/10.1038/onc.2013.230.CrossRefPubMed

33.

Yao Y, Sun F, Lei M. MiRNA-25 inhibits sepsis-induced cardiomyocyte apoptosis by targeting PTEN. Biosci Rep. 2018. https://doi.org/10.1042/bsr20171511.CrossRefPubMedPubMedCentral

34.

Zongaro S, Hukema R, D’Antoni S, et al. The 3′ UTR of FMR1 mRNA is a target of miR-101, miR-129-5p and miR-221: implications for the molecular pathology of FXTAS at the synapse. Hum Mol Genet. 2013;22(10):1971–82. https://doi.org/10.1093/hmg/ddt044.CrossRefPubMed

35.

Mosakhani N, Raty R, Tyybakinoja A, Karjalainen-Lindsberg ML, Elonen E, Knuutila S. MicroRNA profiling in chemoresistant and chemosensitive acute myeloid leukemia. Cytogenet Genome Res. 2013;141(4):272–6. https://doi.org/10.1159/000351219.CrossRefPubMed

36.

Sun H, He L, Ma L, et al. LncRNA CRNDE promotes cell proliferation, invasion and migration by competitively binding miR-384 in papillary thyroid cancer. Oncotarget. 2017;8(66):110552–65. https://doi.org/10.18632/oncotarget.22819.CrossRefPubMedPubMedCentral

37.

Gong J, Liu R, Zhuang R, et al. miR-30c-1* promotes natural killer cell cytotoxicity against human hepatoma cells by targeting the transcription factor HMBOX1. Cancer Sci. 2012;103(4):645–52. https://doi.org/10.1111/j.1349-7006.2012.02207.x.CrossRefPubMedPubMedCentral

38.

Viola D, Giani C, Mazzeo S, et al. KIF5B/RET rearrangement in a carcinoma of the thyroid gland: a case report of a fatal disease. J Clin Endocrinol Metab. 2017;102(9):3091–6. https://doi.org/10.1210/jc.2017-00304.CrossRefPubMed

39.

Subhash S, Andersson PO, Kosalai ST, Kanduri C, Kanduri M. Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL. Clin Epigenet. 2016;8:106. https://doi.org/10.1186/s13148-016-0274-6.CrossRef

40.

Sankar P, Cho MK. Genetics. Toward a new vocabulary of human genetic variation. Science. 2002;298(5597):1337–8. https://doi.org/10.1126/science.1074447.CrossRefPubMedPubMedCentral

41.

Bonham VL, Knerr S. Social and ethical implications of genomics, race, ethnicity, and health inequities. Semin Oncol Nurs. 2008;24(4):254–61. https://doi.org/10.1016/j.soncn.2008.08.005.CrossRefPubMedPubMedCentral

42.

Sharma A, Heuck CJ, Fazzari MJ, et al. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med. 2010;2(6):654–69. https://doi.org/10.1002/wsbm.89.CrossRefPubMed

43.

Dimopoulos K, Gimsing P, Gronbaek K. Aberrant microRNA expression in multiple myeloma. Eur J Haematol. 2013;91(2):95–105. https://doi.org/10.1111/ejh.12124.CrossRefPubMed

44.

Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9(11):1511–20. https://doi.org/10.4161/15592294.2014.983367.CrossRefPubMedPubMedCentral

45.

Taylor E, Morris K, Ellis M, et al. FLT3-ITD positive acute myeloid leukemia: a retrospective analysis of the role of allogeneic transplant and allelic ratio in patient management. Asia Pac J Clin Oncol. 2018. https://doi.org/10.1111/ajco.12827.PubMedCrossRef

46.

Weisberg E, Sattler M, Manley PW, Griffin JD. Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. Oncotargets Ther. 2018;11:175–82. https://doi.org/10.2147/ott.s127679.CrossRef

47.

Shimada A, Iijima-Yamashita Y, Tawa A, et al. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study. Int J Hematol. 2018. https://doi.org/10.1007/s12185-017-2395-x.CrossRefPubMed

48.

Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92(7):2322–33.PubMed

49.

Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov. 2002;1(2):111–21. https://doi.org/10.1038/nrd726.CrossRefPubMed

50.

Mizukawa B, O’Brien E, Moreira DC, et al. The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation. Blood. 2017;130(11):1336–46. https://doi.org/10.1182/blood-2016-12-758458.CrossRefPubMedPubMedCentral

51.

Bruserud O, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 2007;92(3):332–41.CrossRefPubMed

52.

Yilmaz M, Kis C, Ceylan NO, et al. Serum leptin level in acute myeloid leukemia patients. Hematology. 2008;13(1):21–3. https://doi.org/10.1179/102453308x315771.CrossRefPubMed

Title: Identification of long non-coding RNA competing interactions and biological pathways associated with prognosis in pediatric and adolescent cytogenetically normal acute myeloid leukemia
Authors: Xuejiao Yin
Sui Huang
Ruiqi Zhu
Fengjuan Fan
Chunyan Sun
Yu Hu
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2018
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-018-0621-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Transcription factor E2F3a regulates CASP8AP2 transcription and enhances sensitivity to chemotherapeutic drugs in acute lymphoblastic leukemia

Epidermal growth factor-mediated Rab25 pathway regulates integrin β1 trafficking in colon cancer

miR-1236-3p inhibits invasion and metastasis in gastric cancer by targeting MTA2

Loss of PIM1 correlates with progression and prognosis of salivary adenoid cystic carcinoma (SACC)

ZFAS1: a novel tumor-related long non-coding RNA

The experimental study of shunt-decompression arterialized vein flap

Keynote webinar | Spotlight on antibody–drug conjugates in cancer